Stock listing
NASDAQ:ARTL Artelo Biosciences, Inc. Stock
Home listing (NASDAQ) of Artelo Biosciences, Inc.
Follow Artelo Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ARTL
$1.39 USD -0.11 (-7.3%)
Close on Nov 20, 2026
- Day range
- $1.31 – $1.49 USDNov 20, 2026
- Volume
- 51,955 sharesNov 20, 2026
- Market cap
- $1.30M USDAt the close on Nov 20, 2026 · price × 937,177 shares outstanding
- 52-week range
- $1.31 – $179.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.16M USDMedian day 41,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ARTL · Home | $1.39 USD | -0.11 (-7.3%) | 51,955 | $1.46 | $1.49 | $1.31 | $1.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ARTL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.39 | -0.11 | -7.3% | $1.46 | $1.49 | $1.31 | 51,955 | |
| $1.50 | -0.18 | -10.7% | $1.71 | $1.71 | $1.43 | 50,018 | |
| $1.68 | -0.02 | -1.2% | $1.68 | $1.80 | $1.65 | 21,035 | |
| $1.70 | -0.37 | -17.9% | $2.05 | $2.055 | $1.615 | 39,243 | |
| $2.07 | -0.03 | -1.4% | $2.17 | $2.25 | $2.05 | 13,852 | |
| $2.10 | -0.10 | -4.5% | $2.205 | $2.25 | $2.06 | 30,271 | |
| $2.20 | +0.058 | +2.7% | $2.161 | $2.26 | $2.14 | 26,528 | |
| $2.142 | +0.072 | +3.5% | $2.13 | $2.42 | $2.13 | 92,006 | |
| $2.07 | +0.16 | +8.4% | $2.00 | $2.28 | $1.93 | 46,449 | |
| $1.91 | -0.205 | -9.7% | $2.05 | $2.226 | $1.91 | 16,643 | |
| $2.115 | -0.155 | -6.8% | $2.25 | $2.40 | $2.061 | 52,795 | |
| $2.27 | -0.13 | -5.4% | $2.42 | $2.42 | $2.20 | 8,469 | |
| $2.40 | +0.23 | +10.6% | $2.14 | $2.405 | $2.12 | 30,485 | |
| $2.17 | -0.05 | -2.3% | $2.22 | $2.27 | $2.12 | 45,031 | |
| $2.22 | -0.09 | -3.9% | $2.25 | $2.285 | $2.18 | 11,567 | |
| $2.31 | -0.02 | -0.9% | $2.365 | $2.40 | $2.25 | 53,434 | |
| $2.33 | +0.13 | +5.9% | $2.24 | $2.42 | $2.24 | 41,741 | |
| $2.20 | 0.00 | 0.0% | $2.21 | $2.277 | $2.095 | 30,470 | |
| $2.20 | -0.35 | -13.7% | $2.54 | $2.54 | $2.15 | 169,361 | |
| $2.55 | 0.00 | 0.0% | $2.64 | $2.655 | $2.48 | 26,100 | |
| $2.55 | -0.01 | -0.4% | $2.62 | $2.64 | $2.53 | 10,200 | |
| $2.56 | -0.06 | -2.3% | $2.64 | $2.71 | $2.56 | 17,400 | |
| $2.62 | -0.04 | -1.5% | $2.698 | $2.80 | $2.62 | 26,300 | |
| $2.66 | -0.04 | -1.5% | $2.83 | $2.83 | $2.66 | 16,300 | |
| $2.70 | -0.04 | -1.5% | $2.75 | $2.759 | $2.70 | 12,300 | |
| $2.74 | -0.14 | -4.9% | $2.80 | $2.90 | $2.74 | 17,600 | |
| $2.88 | -0.10 | -3.4% | $2.95 | $2.97 | $2.82 | 43,000 | |
| $2.98 | -0.13 | -4.2% | $3.11 | $3.12 | $2.92 | 30,800 | |
| $3.11 | -0.15 | -4.6% | $3.172 | $3.25 | $3.11 | 23,000 | |
| $3.26 | -0.11 | -3.3% | $3.441 | $3.45 | $3.19 | 45,500 | |
| $3.37 | -0.04 | -1.2% | $3.51 | $3.51 | $3.37 | 27,200 | |
| $3.41 | -0.05 | -1.4% | $3.42 | $3.55 | $3.33 | 49,900 | |
| $3.46 | -0.05 | -1.4% | $3.65 | $3.74 | $3.41 | 74,400 | |
| $3.51 | -0.17 | -4.6% | $3.75 | $3.75 | $3.50 | 46,900 | |
| $3.68 | -0.15 | -3.9% | $3.85 | $3.85 | $3.63 | 63,000 | |
| $3.83 | -0.21 | -5.2% | $4.04 | $4.07 | $3.80 | 92,400 | |
| $4.04 | -0.03 | -0.7% | $4.06 | $4.30 | $3.95 | 67,700 | |
| $4.07 | -0.23 | -5.3% | $4.20 | $4.30 | $4.05 | 87,000 | |
| $4.30 | -0.24 | -5.3% | $4.44 | $4.55 | $4.25 | 153,500 | |
| $4.54 | -0.63 | -12.2% | $4.93 | $4.93 | $4.43 | 256,500 | |
| $5.17 | -2.14 | -29.3% | $4.87 | $5.35 | $4.51 | 1,050,400 | |
| $7.31 | +3.16 | +76.1% | $4.03 | $15.73 | $3.90 | 25,129,700 | |
| $4.15 | +0.05 | +1.2% | $4.14 | $4.20 | $3.86 | 324,300 | |
| $4.10 | +0.16 | +4.1% | $3.89 | $4.19 | $3.882 | 71,800 | |
| $3.94 | -0.03 | -0.8% | $4.00 | $4.136 | $3.92 | 29,400 | |
| $3.97 | +0.22 | +5.9% | $3.84 | $4.02 | $3.69 | 124,800 | |
| $3.75 | -1.59 | -29.8% | $4.90 | $4.90 | $3.45 | 276,600 | |
| $5.34 | +0.47 | +9.7% | $4.88 | $5.65 | $4.88 | 89,900 | |
| $4.87 | -0.56 | -10.3% | $5.28 | $5.49 | $4.86 | 54,800 | |
| $5.43 | -0.20 | -3.6% | $5.69 | $5.84 | $5.35 | 41,000 | |
| $5.63 | -0.35 | -5.9% | $5.89 | $6.00 | $5.61 | 41,300 | |
| $5.98 | -0.21 | -3.4% | $6.415 | $6.415 | $5.98 | 29,300 | |
| $6.19 | +0.15 | +2.5% | $6.135 | $6.38 | $5.918 | 10,700 | |
| $6.04 | -0.18 | -2.9% | $6.25 | $6.345 | $5.92 | 27,800 | |
| $6.22 | -0.30 | -4.6% | $6.60 | $6.805 | $6.22 | 27,700 | |
| $6.52 | +0.365 | +5.9% | $6.10 | $6.706 | $5.991 | 43,100 | |
| $6.155 | -0.205 | -3.2% | $6.05 | $6.39 | $5.70 | 84,300 | |
| $6.36 | +0.393 | +6.6% | $5.95 | $6.79 | $5.34 | 587,500 | |
| $5.967 | +0.018 | +0.3% | $5.931 | $6.12 | $5.562 | 29,635 | |
| $5.949 | -0.45 | -7.0% | $6.102 | $6.282 | $4.68 | 10,289 | |
| $6.399 | -0.054 | -0.8% | $6.345 | $6.57 | $6.345 | 1,142 | |
| $6.453 | +0.252 | +4.1% | $6.30 | $6.462 | $6.12 | 1,751 | |
| $6.201 | -0.027 | -0.4% | $6.111 | $6.39 | $5.94 | 1,268 | |
| $6.228 | -0.18 | -2.8% | $6.48 | $6.57 | $6.12 | 1,343 | |
| $6.408 | -0.072 | -1.1% | $6.444 | $6.75 | $6.30 | 4,330 |
Splits
4 splits since 2022 · NASDAQ:ARTL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-9 | Consolidation | |
| 1-for-3 | Consolidation | |
| 1-for-6 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- NASDAQ:ARTL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 25 slides
Latest news
Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
Nov 12, 2026
Closed $2.10 (-4.5%) on Nov 12, 2026
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
Oct 29, 2026
Closed $2.31 (-0.9%) on Oct 29, 2026
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Oct 26, 2026
Closed $2.20 (-13.7%) on Oct 26, 2026
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Oct 7, 2026
Closed $3.41 (-1.4%) on Oct 7, 2026
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Sep 23, 2026
Closed $7.31 (+76.1%) on Sep 23, 2026
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Sep 16, 2026
Closed $3.75 (-29.8%) on Sep 16, 2026
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $6.19 (+2.5%) on Sep 8, 2026
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Aug 17, 2026
Closed $6.49 (-8.7%) on Aug 17, 2026
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Aug 13, 2026
Closed $6.83 (+3.5%) on Aug 13, 2026
Artelo Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 115 in all · newest Nov 12, 2026 · oldest 2019
- Decks
- 7 decks · latest September 2026
Where Artelo Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ARTL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ARTL | BOATS | United States | USD |
Cash and shares
Aug 31, 2026 · Artelo Biosciences — Investor Presentation (September 2026)
- Shares outstanding
- 540,667
Valuation
Price/book 0.2× against a median of 0.3×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.34M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.36
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Artelo Biosciences, Inc. · NASDAQ:ARTL | US$1.30M | US$1.34M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.36 |
| Jupiter Neurosciences, Inc. · NASDAQ:JUNS | US$1.63M | US$1.33M | n/a | 16.9× | n/a | n/a | n/a | n/a | 1.88 |
| Kairos Pharma, Ltd. · AMEX:KAPA | US$1.48M | −US$1.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.36 |
| BioRestorative Therapies, Inc. · NASDAQ:BRTX | US$1.45M | −US$2.11M | n/a | −5.9× | n/a | 0.5× | n/a | 0.0× | 1.81 |
| Nutra Pharma Corp. · OTC:NPHC | US$1.43M | US$13.99M | n/a | 87.0× | n/a | n/a | n/a | n/a | n/a |
| Aptevo Therapeutics Inc. · NASDAQ:APVO | US$1.40M | −US$2.88M | n/a | n/a | n/a | 0.4× | n/a | 1.0× | 0.93 |
| Agentix Corp. · OTC:AGTX | US$1.35M | US$1.34M | n/a | n/a | n/a | n/a | n/a | n/a | -0.73 |
| Clearmind Medicine Inc. · NASDAQ:CMND | US$1.33M | −US$9.01M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.29 |
| International Stem Cell Corporation · OTC:ISCO | US$1.28M | −US$18.76M | 0.1× | −2.0× | n/a | 0.1× | 222.6% | 0.0× | -0.52 |
| SureNano Science Ltd · CSE:SURE | US$1.17M | US$672,335 | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.25 |
| Valion Bio, Inc. · NASDAQ:VBIO | US$1.04M | US$16.34M | n/a | 42.8× | n/a | 0.2× | n/a | 4.1× | 1.11 |
| Median of the others | US$1.37M | −US$488,489 | 0.1× | 16.9× | 0.3× | 222.6% | 0.0× | 0.93 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -9.84 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Gregory Gorgas | President & Chief Executive Officer |
| Mark Spring | Chief Financial Officer |
| Andy Yates | Senior Vice President, Chief Scientific Officer |
| Jason Baybutt | Senior Vice President, Finance |
| Saoirse Elizabeth O’Sullivan | Vice President, Translational Sciences |
| Steven D. Reich | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Connie Matsui | Chair |
| Douglas Blayney | Board Member |
| Greg Reyes | Board Member |
| Gregory Gorgas | President & Chief Executive Officer |
| Martin Emanuele | Board Member |
| Steven Kelly | Board Member |
| Tamara A. Favorito | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 | −5.9% |
| Q2 2026 | Aug 12, 2026 | +1.9% |
| Q1 2026 | May 15, 2026 | −37.6% |
| Q4 2025 | Feb 24, 2026 · Before open | +4.8% |
| Q3 2025 | Nov 12, 2025 · Before open | −8.2% |
| Q2 2025 | Aug 13, 2025 · Before open | +4.2% |
| Q1 2025 | May 13, 2025 · Before open | +3.0% |
| Q4 2024 | Mar 24, 2025 · Before open | −5.7% |
| Q3 2024 | Nov 12, 2024 · Before open | −5.4% |
| Q2 2024 | Aug 13, 2024 · Before open | +2.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | −3.0% |
| Q4 2023 | Mar 25, 2024 · Before open | −0.9% |
| Q3 2023 | Nov 13, 2023 · Before open | 0.0% |
| Q2 2023 | Aug 10, 2023 · Before open | 0.0% |
| Q1 2023 | May 11, 2023 · Before open | −1.4% |
| Q4 2022 | Mar 31, 2023 | +15.6% |
| Q3 2022 | Nov 8, 2022 · Before open | +4.7% |
| Q2 2022 | Aug 9, 2022 · Before open | −23.7% |
| Q1 2022 | May 12, 2022 · Before open | +7.8% |
| Q4 2021 | Jan 12, 2022 · Before open | +0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 25 slides | September 2026 |
| Investor Presentation (November 2019) | Investor deck | 27 slides | Nov 15, 2019 |
| Investor Presentation (June 2019) | Investor deck | 27 slides | June 2019 |
| Investor Presentation (January 2019) | Investor deck | 24 slides | January 2019 |
| Investor Presentation (May 2018) | Investor deck | 28 slides | May 30, 2018 |
| Investor Presentation (March 2018) | Investor deck | 28 slides | March 2018 |
| Investor Presentation (May 2017) | Investor deck | 24 slides | May 16, 2017 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$2M raised · US$4.4 a share · R.F. Lafferty & Co., Inc. Dealers: R.F. Lafferty & Co., Inc. (lead) | Oct 1, 2025 |
| Public offering of shares of common stock and pre-funded warrants Closed: US$3M raised · US$4.4 a share · R. F. Lafferty & Co., Inc. Dealers: R. F. Lafferty & Co., Inc. (lead) | Sep 5, 2025 |
| Private placement of shares of common stock (or pre-funded warrants) and warrants Announced: about US$9.47M · US$10.45 a share · three-year warrants to purchase 906,687 shares at $10.20 per share and three-year… · R. F. Lafferty & Co., Inc. Dealers: R. F. Lafferty & Co., Inc. Buyers: Bartosz Lipiński (lead investor) Use of proceeds: Launch a Solana (SOL)-centric digital asset treasury strategy and support ongoing business | Aug 4, 2025 |
| Private placement of shares of common stock, pre-funded warrants and accompanying warrants Announced: about US$1.43M · accompanying warrants to purchase 460,046 shares at $5.82 per share and 230,023 shares… Use of proceeds: Announce clinical data for ART26.12 and ART27.13 studies; $250,000 to buy SOL digital currency; balance for general corporate and working capital | Jun 26, 2025 |
| At-market convertible notes Closed: US$900,000 raised Use of proceeds: To fund company operations until additional financing is completed | May 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Declared effective by the SEC on Jan 28, 2015. Filed with the SEC to go public on Oct 8, 2014, as KNIGHT KNOX DEVELOPMENT CORP.
- Shares offered
- 8,000,000 shares of common stock
Steps
| Step | When |
|---|---|
| Filed publicly | Oct 8, 2014 |
| Amended twice | Newest Jan 23, 2015 |
| Declared effective by the SEC | Jan 28, 2015 |
| Shares registered with an exchange | Jun 21, 2019 |
| Final prospectus, with the price | Not yet |
Filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | May 15, 2026 |
| UPLOAD · Letter from the SEC | May 11, 2026 |
| CORRESP · Letter to the SEC | Apr 13, 2026 |
| UPLOAD · Letter from the SEC | Apr 13, 2026 |
| CORRESP · Letter to the SEC | Mar 25, 2026 |
| CORRESP · Letter to the SEC | Mar 20, 2026 |
| CORRESP · Letter to the SEC | Mar 20, 2026 |
| UPLOAD · Letter from the SEC | Mar 13, 2026 |
| CORRESP · Letter to the SEC | Dec 1, 2025 |
| CORRESP · Letter to the SEC | Jul 16, 2025 |
All 48 filings
Open IPO · From the cover of the amended prospectus (S-1/A) filed Jan 23, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Research and development | 5.42M | 5.99M | 5.70M | 4.32M | 3.78M | 2.84M | 1.92M | 1.92M | 1.09M | 1.09M |
| Selling, general and administrative | 5.98M | 4.12M | 4.23M | 5.96M | 4.60M | 2.77M | 2.12M | |||
| Operating income | -11.4M | -10.1M | -9.93M | -10.3M | -9.42M | -7.44M | -4.69M | -4.69M | -3.21M | -3.21M |
| Depreciation and amortization | 146.0K | 2.00K | 311 | 500 | 500 | 510 | 510 | |||
| EBITDA | -11.3M | -10.3M | -9.42M | -4.69M | -4.69M | -3.21M | -3.21M | |||
| Interest expense | 194.0K | 0 | 0 | 5.00K | 0 | 0 | 0 | 0 | ||
| Income before tax | -12.9M | -9.83M | -9.29M | -10.1M | -7.44M | -4.66M | -2.17M | |||
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | -60.4K | 0 | -2.04M | 0 |
| Net income | -12.9M | -9.83M | -9.29M | -10.1M | -9.41M | -7.44M | -4.66M | -4.66M | -2.17M | -2.17M |
| Earnings per share, basic | -172.23 | -17.31 | -2.91 | -3.53 | -3.34 | -0.40 | -338.99 | -1.26 | -269.97 | -1.00 |
| Earnings per share, diluted | -12.52 | -18.30 | -3.14 | -0.40 | -1.26 | -1.46 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 600.0K | 2.34M | 2.81M | 6.89M | 12.2M | 6.63M | 2.14M | 2.14M | 4.42M | 4.42M |
| Short-term investments | 0 | 7.61M | 9.15M | 12.0M | 3.44M | 0 | 0 | 1.50K | ||
| Receivables | 8.79K | |||||||||
| Inventory | -8.79K | |||||||||
| Current assets | 695.0K | 2.56M | 11.0M | 18.3M | 24.6M | 10.3M | 2.34M | 2.34M | 4.44M | 4.44M |
| Property, plant and equipment | 90.0K | 246 | 246 | 721 | 721 | |||||
| Total assets | 2.80M | 4.70M | 13.0M | 20.4M | 28.3M | 12.6M | 4.38M | 4.38M | 6.48M | 6.48M |
| Accounts payable | 3.04M | 1.68M | 1.24M | 905.0K | 471.0K | 489.0K | 348.9K | 639.4K | ||
| Current liabilities | 4.04M | 1.77M | 1.29M | 998.0K | 1.03M | 526.0K | 501.0K | 501.0K | 1.02M | 1.02M |
| Total debt | 678.0K | 104.0K | 23.0K | 63.0K | 95.0K | |||||
| Total liabilities | 4.07M | 1.84M | 1.29M | 1.02M | 1.08M | 593.0K | 501.0K | 501.0K | 1.02M | |
| Shareholders' equity | -1.27M | 2.86M | 11.8M | 19.4M | 27.2M | 12.0M | 3.88M | 3.88M | 5.46M | 5.46M |
| Shares outstanding | 74.8K | 567.6K | 3.19M | 2.86M | 2.82M | 1.64M | 13.7K | 4.99M | 8.05K | 3.35M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M | -6.14M | -4.35M | -4.35M | -2.79M | -2.79M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | -1.50M | -1.50M | |||
| Free cash flow | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M | -4.35M | -4.29M | |||
| Cash from investing | -62.0K | 7.77M | 3.51M | 2.96M | -3.44M | -3.44M | -3.44M | 0 | -1.50M | -1.50M |
| Cash from financing | 6.87M | 112.0K | 567.0K | 0 | 14.1M | 14.1M | 1.98M | 1.98M | 8.38M | 8.38M |
| Share buybacks | 9 | -108 | 8.38M | |||||||
| Change in cash | -1.74M | -477.0K | -4.07M | -5.27M | 4.49M | 4.49M | -2.28M | -2.28M | 4.09M | 4.09M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 9, 2026 | Current report | SEC |
| 8-K · Current report | Aug 27, 2026 | Current report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 20, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 17, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jul 16, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jul 15, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jul 2, 2026 | Meeting notice | SEC |
| PRER14A | Jun 22, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Jun 5, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 5, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 5, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 27, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | May 26, 2026 | Meeting notice | SEC |
| 424B5 · Prospectus | May 26, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 20, 2026 | Other filings | SEC |
| 424B5 · Prospectus | May 18, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 15, 2026 | Other filings | SEC |
| 8-K · Current report | May 15, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| S-3/A · Registration statement, amended | May 14, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 11, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 4, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 16, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 16, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 13, 2026 | Other filings | SEC |
| S-1 · Registration statement | Apr 7, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 7, 2026 | Current report | SEC |
| D | Apr 6, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 3, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 31, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 30, 2026 | Material contract | SEC |
| D | Mar 27, 2026 | Other filings | SEC |
| D | Mar 27, 2026 | Other filings | SEC |
| D | Mar 27, 2026 | Other filings | SEC |
| RW · Request to withdraw a registration | Mar 27, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 26, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Mar 26, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 25, 2026 | Other filings | SEC |
| S-1 · Registration statement | Mar 24, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 24, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 23, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 20, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 20, 2026 | Other filings | SEC |
| S-1 · Registration statement | Mar 20, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 18, 2026 | Material contract | SEC |
| 8-K · Current report | Mar 17, 2026 | Results | SEC |
| UPLOAD · Letter from the SEC | Mar 13, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Mar 9, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2026 | Current report | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| D | Feb 5, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 5, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jan 16, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Jan 7, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 2, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Dec 11, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Dec 11, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Dec 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 1, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 25, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Nov 17, 2025 | Insider trade | SEC |
| S-1 · Registration statement | Nov 17, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| D | Nov 10, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 31, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 27, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 21, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 17, 2025 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 1, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 1, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 30, 2025 | Offer document | SEC |
| DRS · Draft registration statement | Sep 29, 2025 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 19, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 15, 2025 | Current report | SEC |
| 8-K · Current report | Sep 10, 2025 | Current report | SEC |
| 8-K · Current report | Sep 5, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 5, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 4, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 4, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 8-K · Current report | Aug 29, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| D | Aug 13, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Aug 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Aug 7, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 4, 2025 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Jul 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 18, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 18, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 18, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 16, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 16, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jul 11, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 11, 2025 | Results | SEC |
| D | Jul 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 13, 2025 | Current report | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 8-K · Current report | May 1, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 20, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 8, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 8, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Nov 8, 2024 | Annual report | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 25-NSE | Jun 17, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2023 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jul 17, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 12, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 10, 2023 | Other filings | SEC |
| DEL AM | Jul 7, 2023 | Other filings | SEC |
| S-3 · Registration statement | Jul 6, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 3, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 16, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 16, 2023 | Meeting notice | SEC |
| ARS · Annual report to shareholders | May 16, 2023 | Annual report | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | May 5, 2023 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Apr 21, 2023 | Offer document | SEC |
| 8-K · Current report | Apr 21, 2023 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Sep 16, 2022 | Meeting outcome | SEC |
| 8-K · Current report | Aug 25, 2022 | Current report | SEC |
| 4 · Change in ownership | Aug 12, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2022 | Insider trade | SEC |
| 8-K · Current report | Aug 9, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Aug 9, 2022 | Quarterly report | SEC |
This page holds 200 of 466 filings. Open Filings
Cap table
Built by 6ix from Artelo Biosciences, Inc.’s releases · as of Nov 11, 2026
- Common shares
- 937,177
- Fully diluted
- 937,177
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 937,177 | Nov 11, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 937,177 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Georgia Erbez Other companies: Codexis, Inc. (Chief Financial Officer and Chief Business Officer · Since at least Sep 30, 2024); Coherus Oncology, Inc. (Director · Since at least Feb 20, 2024); Sierra Oncology Inc (Director · Jun 2, 2021 – Jul 1, 2022 · Past); Harpoon Therapeutics Inc (Chief Financial Officer · Feb 7, 2019 – Jan 28, 2022 · Past); Zosano Pharma Corp (CFO and Chief Business Officer · Jun 15, 2016 – May 25, 2017 · Past); Asterias Biotherapeutics Inc (Exec VP & CFO · Nov 9, 2015 – Nov 9, 2015 · Past); Raptor Pharmaceutical Corp (Chief Financial Officer · Sep 10, 2012 – May 13, 2014 · Past) | Director · Jun 21, 2019 – Aug 29, 2019 · Past |
| Tamara A. Favorito Other companies: Zevra Therapeutics, Inc. (Chairperson of the Board, Audit Committee Chair · Since at least Aug 18, 2021); TuHURA Biosciences, Inc. (Director · Apr 29, 2021 – Aug 30, 2023 · Past); Viridian Therapeutics, Inc. (CFO, Secretary, Treasurer · Aug 4, 2014 – Oct 31, 2016 · Past) | Board Member · Since at least Mar 3, 2021 |
| Connie Matsui Other companies: Sutro Biopharma, Inc. (Chair, Board of Directors · Since at least Jun 24, 2019); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – Nov 29, 2024 · Past) | Chair · Since at least Jun 21, 2019 |
| John W Beck Other companies: AIxCrypto Holdings, Inc. (Chief Financial Officer · May 23, 2018 – May 18, 2020 · Past); Ardea Biosciences Inc (SVP, Finance & Operations, CFO · Jun 15, 2007 – Jun 19, 2012 · Past) | Director · Dec 6, 2019 – Jul 16, 2021 · Past |
| Robert Martin Emanuele Other companies: Savara, Inc. (Senior VP, Development · Apr 27, 2011 – Jan 4, 2016 · Past); Avanir Pharmaceuticals Inc (V P, Business Development · May 25, 2006 – May 25, 2006 · Past) | Director · Since at least Jun 21, 2019 |
| Gregory Gorgas Other companies: Savara, Inc. (Senior VP, Commercial · Jul 21, 2011 – Jan 4, 2016 · Past) | President & Chief Executive Officer · Since at least Jun 21, 2019 |
| Gregory Reyes Other companies: Bio Green Med Solution, Inc. (Senior VP, Research · Jun 22, 2007 – Dec 22, 2007 · Past) | Director · Since at least Nov 30, 2020 |
| Steven Kelly Other companies: Carisma Therapeutics, Inc. (President and CEO, Director · Mar 7, 2023 – Jan 28, 2025 · Past) | Director · Since at least Jun 21, 2019 |
| Andy Yates | Senior Vice President, Chief Scientific Officer · Since at least Sep 29, 2025 |
| Douglas Blayney | Board Member · Since at least Jun 21, 2019 |
All 17 people
| Person | Seat |
|---|---|
| Greg Reyes | Board Member · Since at least Nov 4, 2026 |
| Jason Baybutt | Senior Vice President, Finance · Since at least Nov 5, 2026 |
| Mark Spring | Chief Financial Officer · Since at least Oct 27, 2025 |
| Martin Emanuele | Board Member · Since at least Nov 5, 2026 |
| Saoirse Elizabeth O’Sullivan | Vice President, Translational Sciences · Since at least Oct 29, 2026 |
| Steven D. Reich | Chief Medical Officer · Since at least Sep 29, 2025 |
| Steven Kelly | Board Member · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Artelo Biosciences, Inc.